Pharmaceutical Innovation

Work

Pharmaceutical Innovation and the Inflation Reduction Act: 2023 in Review 

We’re back for our half-year check-in on pharma R&D, our first since CMS selected the first 10 drugs for Medicare negotiation. In this report, we examine how 19 of the largest biopharma companies approached investment in R&D, M&A, and licensing in 2023.
Read More Read More